Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Dayton, OH
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Sylvania, OH
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Sylvania, OH
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Lake Oswego, OR
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Medford, OR
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Portland, OR
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Allentown, PA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Allentown, PA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Downington, PA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Downington, PA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Elverson, PA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Elverson, PA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Erie, PA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Swarthmore, PA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Swarthmore, PA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
East Providence, RI
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
East Providence, RI
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Charleston, SC
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Gaffney, SC
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Greer, SC
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Simpsonville, SC
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Bristol, TN
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Chattanooga, TN
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Johnson City, TN
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Knoxville, TN
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Corsicana, TX
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Corsicana, TX
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Dallas, TX
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
San Antonio, TX
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Richmond, VA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Bellingham, WA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Bellingham, WA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Spokane, WA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Tacoma, WA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Morgantown, WV
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Milwaukee, WI
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma
Protein Biomarker Discovery and Validation in COPD And Asthma
Status: Enrolling
Updated:  11/2/2016
University of Texas Medical Branch
mi
from
Galveston, TX
Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma
Protein Biomarker Discovery and Validation in COPD And Asthma
Status: Enrolling
Updated: 11/2/2016
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Alabama, AL
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Alabama, AL
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Arizona, AZ
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Arizona, AZ
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in California, CA
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in California, CA
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ATLANA Pharma
mi
from
Cities in Colorado, CO
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ATLANA Pharma
mi
from
Cities in Colorado, CO
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Conneticut, CT
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Conneticut, CT
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Delaware, DE
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Delaware, DE
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Florida, FL
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Florida, FL
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Georgia, GA
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Georgia, GA
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Idaho, ID
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Idaho, ID
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Indiana, IN
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Indiana, IN
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Iowa, IA
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Iowa, IA
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Kansas, KA
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Kansas, KA
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Kentucky, KY
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Kentucky, KY
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Louisiana, LA
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Louisiana, LA
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Maryland, MD
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Maryland, MD
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Michigan, MI
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Michigan, MI
Click here to add this to my saved trials
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/22/2016
ALTANA Pharma
mi
from
Cities in Missouri, MO
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/22/2016
ALTANA Pharma
mi
from
Cities in Missouri, MO
Click here to add this to my saved trials